Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03366012 · ClinicalTrials.gov registry record · NA
Rapid Assessment of Esophageal Adenocarcinoma Risk Test
A NA study, sponsored by Columbia University.
- Terminated
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT03366012 is a NA study that was terminated before completion, run by Columbia University. The registered enrollment target is 51 participants.
The verdict
NCT03366012, a NA study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study aims to evaluate the acceptability of a new non-invasive screening device to test for Barrett's esophagus. The investigators will prospectively enroll 100 patients to undergo Cytosponge testing. The time of involvement for an individual will range from 2 weeks to 2 months, depending on the results of the Cytosponge test and time to follow up endoscopy, if indicated.
Interventions
- DEVICE Cytosponge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2023-05-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03366012
The ClinicalTrials.gov registry entry for NCT03366012 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cytosponge is the first listed.
NCT03366012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03366012 about?
NCT03366012 is a clinical study titled "Rapid Assessment of Esophageal Adenocarcinoma Risk Test". This study aims to evaluate the acceptability of a new non-invasive screening device to test for Barrett's esophagus. The investigators will prospectively enroll 100 patients to undergo Cytosponge testing. The time of involvement for an individual will range from 2 weeks to 2 months, depending on th...
What is the current status of trial NCT03366012?
This trial is currently terminated. It is a NA study. The enrollment target is 51 participants. The study started on 2018-08-01. Estimated completion is 2023-05-19.
What interventions are being tested in trial NCT03366012?
The interventions under investigation include: Cytosponge (DEVICE).
Who is sponsoring clinical trial NCT03366012?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.